These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28489605)

  • 1. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.
    Iżykowska K; Przybylski GK; Gand C; Braun FC; Grabarczyk P; Kuss AW; Olek-Hrab K; Bastidas Torres AN; Vermeer MH; Zoutman WH; Tensen CP; Schmidt CA
    Oncotarget; 2017 Jun; 8(24):39627-39639. PubMed ID: 28489605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of multiple complex rearrangements associated with deletions in the 6q23-27 region in Sézary syndrome.
    Iżykowska K; Zawada M; Nowicka K; Grabarczyk P; Braun FCM; Delin M; Möbs M; Beyer M; Sterry W; Schmidt CA; Przybylski GK
    J Invest Dermatol; 2013 Nov; 133(11):2617-2625. PubMed ID: 23698072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.
    da Silva Almeida AC; Abate F; Khiabanian H; Martinez-Escala E; Guitart J; Tensen CP; Vermeer MH; Rabadan R; Ferrando A; Palomero T
    Nat Genet; 2015 Dec; 47(12):1465-70. PubMed ID: 26551667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome.
    Prasad A; Rabionet R; Espinet B; Zapata L; Puiggros A; Melero C; Puig A; Sarria-Trujillo Y; Ossowski S; Garcia-Muret MP; Estrach T; Servitje O; Lopez-Lerma I; Gallardo F; Pujol RM; Estivill X
    J Invest Dermatol; 2016 Jul; 136(7):1490-1499. PubMed ID: 27039262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome.
    Caprini E; Bresin A; Cristofoletti C; Helmer Citterich M; Tocco V; Scala E; Monopoli A; Benucci R; Narducci MG; Russo G
    Cell Death Dis; 2018 Dec; 9(12):1178. PubMed ID: 30518749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sézary syndrome: old enigmas, new targets.
    Nicolay JP; Felcht M; Schledzewski K; Goerdt S; Géraud C
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):256-64. PubMed ID: 26972187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
    Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
    Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts.
    Lee CS; Ungewickell A; Bhaduri A; Qu K; Webster DE; Armstrong R; Weng WK; Aros CJ; Mah A; Chen RO; Lin M; Sundram U; Chang HY; Kretz M; Kim YH; Khavari PA
    Blood; 2012 Oct; 120(16):3288-97. PubMed ID: 22936659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelotyping in mycosis fungoides and Sézary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p.
    Scarisbrick JJ; Woolford AJ; Russell-Jones R; Whittaker SJ
    J Invest Dermatol; 2001 Sep; 117(3):663-70. PubMed ID: 11564174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylation of the promoter region drives ectopic expression of TMEM244 in Sézary cells.
    Iżykowska K; Rassek K; Żurawek M; Nowicka K; Paczkowska J; Ziółkowska-Suchanek I; Podralska M; Dzikiewicz-Krawczyk A; Joks M; Olek-Hrab K; Giefing M; Przybylski GK
    J Cell Mol Med; 2020 Sep; 24(18):10970-10977. PubMed ID: 32794659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel and highly recurrent chromosomal alterations in Sézary syndrome.
    Vermeer MH; van Doorn R; Dijkman R; Mao X; Whittaker S; van Voorst Vader PC; Gerritsen MJ; Geerts ML; Gellrich S; Söderberg O; Leuchowius KJ; Landegren U; Out-Luiting JJ; Knijnenburg J; Ijszenga M; Szuhai K; Willemze R; Tensen CP
    Cancer Res; 2008 Apr; 68(8):2689-98. PubMed ID: 18413736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma.
    Persson M; Andrén Y; Moskaluk CA; Frierson HF; Cooke SL; Futreal PA; Kling T; Nelander S; Nordkvist A; Persson F; Stenman G
    Genes Chromosomes Cancer; 2012 Aug; 51(8):805-17. PubMed ID: 22505352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.
    Wang L; Ni X; Covington KR; Yang BY; Shiu J; Zhang X; Xi L; Meng Q; Langridge T; Drummond J; Donehower LA; Doddapaneni H; Muzny DM; Gibbs RA; Wheeler DA; Duvic M
    Nat Genet; 2015 Dec; 47(12):1426-34. PubMed ID: 26551670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosome aberrations, spontaneous SCE, and growth kinetics in PHA-stimulated lymphocytes of five cases with Sézary syndrome.
    Limon J; Nedoszytko B; Brozek I; Hellmann A; Zajaczek S; Lubiński J; Mrózek K
    Cancer Genet Cytogenet; 1995 Aug; 83(1):75-81. PubMed ID: 7656210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
    Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
    Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic tools in Sezary syndrome.
    Möbs M; Knott M; Fritzen B; Pullmann S; Sterry W; Assaf C
    G Ital Dermatol Venereol; 2010 Jun; 145(3):385-91. PubMed ID: 20461046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.
    Weng WK; Armstrong R; Arai S; Desmarais C; Hoppe R; Kim YH
    Sci Transl Med; 2013 Dec; 5(214):214ra171. PubMed ID: 24307695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
    Butler RM; McKenzie RC; Jones CL; Flanagan CE; Woollard WJ; Demontis M; Ferreira S; Tosi I; John S; Whittaker SJ; Mitchell TJ
    J Invest Dermatol; 2019 Sep; 139(9):1975-1984.e2. PubMed ID: 30910759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 alterations in primary and secondary Sézary syndrome: A diagnostic tool for the assessment of malignancy in patients with erythroderma.
    Gros A; Laharanne E; Vergier M; Prochazkova-Carlotti M; Pham-Ledard A; Bandres T; Poglio S; Berhouet S; Vergier B; Vial JP; Chevret E; Beylot-Barry M; Merlio JP
    PLoS One; 2017; 12(3):e0173171. PubMed ID: 28301507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sézary Syndrome: Translating Genetic Diversity into Personalized Medicine.
    Chevret E; Merlio JP
    J Invest Dermatol; 2016 Jul; 136(7):1319-1324. PubMed ID: 27342034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.